TRIM33 and myositis disease: Thus, it is reasonable to hypothesize that somatic mutations of TIF1γ, NXP2, or HMGCR genes in tumors may provoke a specific antitumoral immune response which may secondarily extend to the target organs of myositis (muscle, skin) by cross-reactivity and/or a process of epitope spreading (Figure 3).